Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
Newby LK, Bhapkar MV, White HD, Moliterno DJ, LaPointe NM, Kandzari DE, Verheugt FW, Kramer JM, Armstrong PW, Califf RM; SYMPHONY and 2nd SYMPHONY investigators. Newby LK, et al. Among authors: moliterno dj. J Thromb Thrombolysis. 2003 Dec;16(3):119-28. doi: 10.1023/B:THRO.0000024050.78728.35. J Thromb Thrombolysis. 2003. PMID: 15087598 Clinical Trial.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Mak KH, et al. Among authors: moliterno dj. J Am Coll Cardiol. 1997 Jul;30(1):171-9. doi: 10.1016/s0735-1097(97)00118-6. J Am Coll Cardiol. 1997. PMID: 9207639 Free article. Clinical Trial.
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Topol EJ, et al. Among authors: moliterno dj. Circulation. 2000 Oct 10;102(15):1761-5. doi: 10.1161/01.cir.102.15.1761. Circulation. 2000. PMID: 11023929 Clinical Trial.
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Newby LK, et al. Among authors: moliterno dj. Circulation. 2001 Jun 19;103(24):2891-6. doi: 10.1161/01.cir.103.24.2891. Circulation. 2001. PMID: 11413076 Clinical Trial.
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW; PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. Kaul P, et al. Among authors: moliterno dj. J Am Coll Cardiol. 2001 Jul;38(1):64-71. doi: 10.1016/s0735-1097(01)01307-9. J Am Coll Cardiol. 2001. PMID: 11451297 Free article.
386 results